# James C. Yao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/james-c-yao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,535 |
| Field | Neuroendocrine Tumor Research Advances |
| h-index | 81 |
| i10-index | 233 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5043534982 |
| ORCID iD | 0000-0002-1875-3962 |
| Works | 596 |

## Researcher papers

Showing 12 of 20.

- [One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States](https://scholariq.org/papers/one-hundred-years-after-carcinoid-epidemiology-of-and-prognostic-factors-for/)
- [Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States](https://scholariq.org/papers/trends-in-the-incidence-prevalence-and-survival-outcomes-in-patients-with/)
- [Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors](https://scholariq.org/papers/phase-3-trial-of-sup-177-sup-lu-dotatate-for-midgut-neuroendocrine-tumors/)
- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-for-the-treatment-of-advanced-non-functional-neuroendocrine-tumours/)
- [Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/everolimus-plus-octreotide-long-acting-repeatable-for-the-treatment-of-advanced/)
- [Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial](https://scholariq.org/papers/daily-oral-everolimus-activity-in-patients-with-metastatic-pancreatic/)
- [Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study](https://scholariq.org/papers/efficacy-of-rad001-everolimus-and-octreotide-lar-in-advanced-low-to-intermediate/)
- [Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas](https://scholariq.org/papers/fluorouracil-doxorubicin-and-streptozocin-in-the-treatment-of-patients-with/)
- [Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors](https://scholariq.org/papers/consensus-guidelines-for-the-management-and-treatment-of-neuroendocrine-tumors/)
- [NANETS Treatment Guidelines](https://scholariq.org/papers/nanets-treatment-guidelines/)
- [The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors](https://scholariq.org/papers/the-nanets-consensus-guideline-for-the-diagnosis-and-management-of/)

## Researcher topics

- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.